SpyGlass Pharma continues advancing its BIM-IOL System, an innovative drug delivery intraocular lens designed for sustained glaucoma treatment over three years. As of Q1 2026, the company holds approximately $239 million in cash, supporting ongoing Phase 3 trials with enrollment expected to complete by 2027. The business model integrates glaucoma treatment into routine cataract surgery, addressing adherence challenges linked to topical medications. While SpyGlass benefits from exclusive intellectual property rights and promising clinical data, risks remain from clinical and regulatory dependencies, IP litigation, and surgeon adoption uncertainties.